The side effects so far have been mild to moderate, like skin rash or feeling tired, and no life-threatening side-effects popped up during testing.
Because of these strong results, the US Food and Drug Administration included daraxonrasib in the first group to receive National Priority Voucher status.
While final approval is still pending, patients with few other options can already access it through expanded access programs.